itolizumab

Ligand id: 9421

Name: itolizumab

References
1. Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, Chinea G, Montero E. (2008)
Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.
Hybridoma (Larchmt)27 (4): 291-301. [PMID:18707547]
2. Dogra S, D S K, Budamakuntla L, Srinivas CR, Khopkar U, Gupta S, Shetty N, Pratap DV, Gopal MG, Rao TN et al.. (2015)
Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
J. Am. Acad. Dermatol.73 (2): 331-3.e1. [PMID:26183983]
3. Jayaraman K. (2013)
Biocon's first-in-class anti-CD6 mAb reaches the market.
Nat. Biotechnol.31 (12): 1062-3. [PMID:24316625]
4. Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR et al.. (2014)
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
J. Am. Acad. Dermatol.71 (3): 484-92. [PMID:24703722]
5. Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernandez IM, Hernandez MV, Martinez JP, Hernandez X et al.. (2012)
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Results Immunol2: 204-11. [PMID:24371585]